CTSL antibodies function by binding to specific epitopes on the CTSL protein, thereby inhibiting its proteolytic activity. This disruption blocks CTSL’s ability to cleave target substrates, such as viral spike proteins, which are essential for viral entry into host cells. For example, studies demonstrate that CTSL cleaves the SARS-CoV-2 spike protein, facilitating viral fusion and infection . Antibody-mediated inhibition of CTSL has been shown to reduce pseudovirus infection in vitro by up to 76% .
CTSL expression is elevated in COVID-19 patients and correlates with disease severity . Experimental data reveal that CTSL knockdown significantly reduces SARS-CoV-2 pseudovirus entry into host cells, while overexpression enhances infection . Amantadine, a licensed anti-influenza drug, has been identified as a CTSL inhibitor, demonstrating therapeutic potential .
A humanized antibody fusion (Syn-LC-CTSLpp) has been engineered by fusing the inhibitory propeptide of procathepsin L to an antibody scaffold. This construct exhibits a K_i of 0.090 ± 0.015 nM for CTSL, with >100-fold specificity over related proteases like CTSS . The antibody’s binding affinity (K_D = 5.495 nM) and stability under physiological conditions make it a promising candidate for therapeutic applications .
High CTSL expression in lung and glioma tissues correlates with poor prognosis, suggesting its role in tumor progression . Antibodies targeting CTSL may inhibit cancer-associated proteolysis while reducing SARS-CoV-2 susceptibility in cancer patients .
Commercial antibodies like MAB9521 (R&D Systems) enable detection of CTSL in Western blots and IHC. This antibody shows no cross-reactivity with other cathepsins (e.g., CTSB, CTSS) and specifically binds CTSL at ~35 kDa .
Syn-LC-CTSLpp: A humanized antibody fusion with subnanomolar CTSL inhibition .
Amantadine: A repurposed drug shown to inhibit CTSL activity post-infection .